Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $50,220.30 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 128,770 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $0.39, for a total transaction of $50,220.30. Following the sale, the insider directly owned 341,353 shares in the company, valued at $133,127.67. This trade represents a 27.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $55,361.25.
• On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $68,176.40.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock opened at $0.35 on Friday. The stock has a market capitalization of $17.07 million, a price-to-earnings ratio of -0.28 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 52-week low of $0.34 and a 52-week high of $2.38. The stock’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $0.69.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on HOWL shares. Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $3.75.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Regal Investment Advisors LLC increased its position in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at about $48,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC increased its holdings in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.